Biological
Grass MATA MPL
Grass MATA MPL is a biological therapy with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
2
40%
Ph phase_3
1
20%
Phase Distribution
2
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine
NCT00133146
completedphase_1
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
NCT03931993
completedphase_3
Efficacy and Safety/Tolerability of Grass MATA MPL
NCT00414141
completedphase_2
Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen
NCT00104377
completedphase_1
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
NCT00104390
Clinical Trials (5)
Showing 5 of 5 trials
NCT00133146Phase 2
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine
NCT03931993Phase 1
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
NCT00414141Phase 3
Efficacy and Safety/Tolerability of Grass MATA MPL
NCT00104377Phase 2
Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen
NCT00104390Phase 1
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5